Business Context and Reporting Period
Aptevo Therapeutics Inc. (ATI) filed a Form 8-K on February 28, 2020, reporting the completion of a material definitive agreement and asset disposition. On this date, ATI sold all issued and outstanding interests of its wholly owned subsidiary, Aptevo BioTherapeutics LLC ("Aptevo BioT"), to Medexus Pharma, Inc. ("Medexus"). The transaction transferred ownership of IXINITY, a coagulation factor IX product approved by the FDA for hemophilia B treatment.
Key Financial Metrics and Transaction Terms
- Closing Consideration: ATI received $30 million in cash, subject to customary adjustments for cash, indebtedness, working capital, and transaction expenses.
- Escrow Deposit: Medexus deposited $912,500 with an escrow agent to fund potential post-closing adjustments and indemnification obligations.
- Deferred Payments: ATI is eligible for royalties equal to a low-single digit percentage of net sales in the U.S. and Canada, increasing to a mid-single digit percentage after the completion of a U.S. pediatric trial or June 30, 2022. Payments continue for up to 15 years.
- Milestone Payments:
- $1 million upon Health Canada approval.
- Up to $5 million total ($1 million each) for regulatory approvals in Germany, France, the U.K., Spain, and Italy.
- $5 million if worldwide net sales exceed $120 million in a fiscal year post-closing.
- Debt Repayment: ATI utilized a portion of the sale proceeds to pay off all indebtedness and obligations under its Amended and Restated Credit and Security Agreement dated August 6, 2018.
Material Changes Versus Prior Period
This filing represents a significant structural change for ATI, marking the divestiture of its primary commercial asset (IXINITY) and its associated subsidiary. Unlike prior periods where ATI retained ownership and operational control of the product, the company has transitioned to a royalty-based revenue model for this asset. Additionally, the company has eliminated its outstanding debt load, a material change in its capital structure compared to the period prior to February 28, 2020.
Outlook, Risks, and Contingencies
Outlook: Future cash flows from this transaction depend on the commercial performance of IXINITY in the U.S. and Canada and the achievement of specific regulatory and sales milestones. The deferred payment structure includes a provision for reduction if a biosimilar launch causes a sustained price decrease for three consecutive quarters, though rates would revert to the original mid-single digit percentage thereafter.
Risks and Contingencies:
- Adjustments: The final closing consideration is subject to post-closing adjustments based on working capital and other estimates.
- Indemnification: While Medexus purchased a representations and warranties insurance policy, ATI remains liable for certain breaches to the extent the policy limits are exhausted.
- Survival Period: Representations and warranties survive for 15 months, with fundamental representations surviving for 60 days after the applicable statute of limitations expires.
Investor Verification Checklist
- Verify the final post-closing adjustment amount to determine the exact cash proceeds received beyond the initial $30 million estimate.
- Confirm the specific "low-single digit" and "mid-single digit" royalty percentages defined in the full Purchase Agreement (Exhibit 2.1).
- Review the unaudited pro forma condensed consolidated financial statements (Exhibit 99.1) to assess the impact of the debt payoff and asset sale on ATI's remaining balance sheet.
- Monitor the status of the U.S. pediatric trial for IXINITY, as its completion triggers an increase in royalty rates.
- Assess the remaining cash position of ATI after the debt repayment to evaluate liquidity for future operations or R&D.